Vopratelimab

Names

[ CAS No. ]:
2039148-04-2

[ Name ]:
Vopratelimab

Biological Activity

[Description]:

Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[In Vitro]

Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T 细胞) 具有激活原代人 T 细胞的活性，驱动 IFNγ、IL-17a、IL-10、IL-9、GM-CSF、TNFα 和 IL-21 分泌[1]。

[In Vivo]

Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; 每周两次，持续 2 周) 促进 Sa1/N 小鼠同基因肿瘤模型中的肿瘤消退[1]。 Animal Model: Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model[1] Dosage: 0.25-0.3 mg/kg Administration: Intraperitoneal injection; twice a week, for 2 weeks Result: Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.

[References]

[1]. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.